Prenetics Global (NASDAQ:PRE) Issues Earnings Results, Misses Expectations By $0.63 EPS

Prenetics Global logo with Consumer Staples background
Image from MarketBeat Media, LLC.

Key Points

  • Prenetics reported quarterly EPS of -$1.45, missing analyst expectations of -$0.82 by $0.63, while revenue of $64.1 million slightly beat estimates of $63.2 million.
  • Revenue rose 37.9% sequentially, led by IM8, and repeat orders made up 59% of billings; management also cited declining customer acquisition costs and strong returns from early customer cohorts.
  • The company raised its expected second-half adjusted EBITDA loss to $30 million–$35 million from $8 million–$12 million as it increased growth spending, while reaffirming 2026 revenue guidance of $220 million–$230 million.
  • Interested in Prenetics Global? Here are five stocks we like better.

Prenetics Global (NASDAQ:PRE - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($1.45) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.63), FiscalAI reports. The business had revenue of $64.11 million during the quarter, compared to analyst estimates of $63.18 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%.

Here are the key takeaways from Prenetics Global's conference call:

  • Q3 revenue rose 37.9% sequentially to $64.1 million, with IM8 contributing $62.9 million; September was a record month. The company said quarterly customer acquisition costs declined for a second consecutive quarter, to about $285.
  • Management reported strong customer returns: its earliest cohort has generated $4.10 in gross profit per acquisition dollar, while the next 91,000 customers are at about $2.70 and are expected to reach 3.0 early in 2027. Repeat orders accounted for 59% of quarterly billings, and the company ended September with about 160,000 active subscriptions.
  • Prenetics raised its expected second-half adjusted EBITDA loss to $30 million–$35 million, from $8 million–$12 million previously, as it chose to increase growth spending. Q3 adjusted EBITDA loss was $12.7 million; management said Q4 spending will remain elevated if customer returns hold.
  • The company reaffirmed 2026 revenue guidance of $220 million–$230 million and its 2027 IM8 revenue target of at least $400 million, based on current products. Hydration and Care Bears products, planned for 2027, plus potential retail and China launches are excluded from that target and remain subject to execution and partnership or regulatory requirements.

Prenetics Global Price Performance

Shares of PRE traded down $7.01 during mid-day trading on Wednesday, hitting $9.32. The company's stock had a trading volume of 537,814 shares, compared to its average volume of 227,387. The firm has a 50-day moving average price of $20.08 and a 200 day moving average price of $19.53. Prenetics Global has a fifty-two week low of $9.13 and a fifty-two week high of $27.24. The stock has a market capitalization of $157.23 million, a price-to-earnings ratio of -2.24 and a beta of 0.40.

More Prenetics Global News

These are some of the PRE news items that stood out recently:

  • Positive Sentiment: IM8 reported that its earliest customer cohort generated gross profit equal to about 4.1 times its acquisition cost in under two years. Prenetics also reported $4.1 million in adjusted free cash flow and cash and current financial assets of $111.5 million at quarter-end. IM8 revenue and customer economics
  • Neutral Sentiment: The FY2026 revenue outlook of $220–230 million includes the analyst consensus estimate of $224.3 million, so the reaffirmed range did not signal a clear forecast upgrade. Prenetics revenue update
  • Negative Sentiment: Prenetics reported a quarterly loss of $25.4 million and EPS of negative $1.45, missing the consensus estimate of negative $0.82. The company also raised its expected second-half adjusted EBITDA loss to $30–35 million from $8–12 million, citing increased customer-acquisition investment. Prenetics Q3 2026 results and outlook

Insiders Place Their Bets

In other Prenetics Global news, CFO Brian Rosin acquired 18,000 shares of Prenetics Global stock in a transaction that occurred on Monday, August 24th. The stock was purchased at an average cost of $21.19 per share, with a total value of $381,420.00. Following the purchase, the chief financial officer owned 18,000 shares in the company, valued at approximately $381,420. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Danny Sheng Wu Yeung purchased 17,181 shares of the firm's stock in a transaction that occurred on Monday, August 24th. The shares were bought at an average price of $21.23 per share, with a total value of $364,752.63. Following the completion of the acquisition, the chief executive officer owned 112,416 shares of the company's stock, valued at $2,386,591.68. This trade represents a 18.04% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 47,781 shares of company stock worth $999,778 in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PRE shares. B. Riley Financial initiated coverage on Prenetics Global in a research note on Thursday, August 27th. They issued a "buy" rating and a $37.00 price target on the stock. Lucid Cap Mkts upgraded shares of Prenetics Global to a "strong-buy" rating in a report on Monday, October 12th. Craig Hallum assumed coverage on shares of Prenetics Global in a research report on Thursday, September 17th. They issued a "buy" rating and a $40.00 target price on the stock. Maxim Group assumed coverage on shares of Prenetics Global in a research report on Monday, October 26th. They set a "buy" rating and a $41.00 price target for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Prenetics Global in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $37.17.

View Our Latest Stock Report on Prenetics Global

About Prenetics Global

(Get Free Report)

Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.

Featured Stories

Earnings History for Prenetics Global (NASDAQ:PRE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prenetics Global Right Now?

Before you consider Prenetics Global, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.

While Prenetics Global currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines